Welcome to our dedicated page for Insulet news (Ticker: PODD), a resource for investors and traders seeking the latest updates and insights on Insulet stock.
Insulet Corporation (PODD) delivers innovative diabetes management solutions through its flagship Omnipod® insulin pump system. This page aggregates official news and developments about the company's medical device innovations, financial performance, and strategic initiatives.
Investors and healthcare professionals will find timely updates including quarterly earnings reports, product launch announcements, regulatory milestones, and partnership agreements. All content is sourced directly from verified corporate communications to ensure accuracy.
Key coverage areas include FDA clearances for new devices, clinical study results, international market entries, and technology partnerships enhancing insulin delivery systems. The resource is particularly valuable for tracking advancements in tubeless pump technology and automated insulin dosing integrations.
Bookmark this page for streamlined access to Insulet's latest developments in diabetes care innovation. Check regularly for updates that may impact long-term growth strategies or patient care standards.
Insulet (NASDAQ:PODD) launched the “The Day Diabetes Showed Up to Work” campaign for Diabetes Awareness Month beginning November 1, 2025, sharing a global survey of 9,656 workers and new workplace resources.
Key findings: >1 in 3 respondents report mental strain from diabetes; 42% of people with diabetes (PWD) reported workplace-related anxiety; 79% of PWD faced bias; 27% fear diabetes limits opportunities; 21% conceal their condition; 61% of colleagues cannot identify type 1 symptoms. Insulet will publish a whitepaper, infographics, checklists, personal stories, and donate via its Insulet for Good program to ADA and IDF.
Insulet (NASDAQ: PODD) announced the appointment of Robert L. Huffines to its board of directors, effective October 31, 2025.
Mr. Huffines, a former Global Chair of Investment Banking at JP Morgan Chase & Co., joins as an independent director and will serve on the board's Audit Committee. The company highlighted his more than three decades advising healthcare companies and said his strategic insight will support Insulet's growth and shareholder value.
Insulet (NASDAQ: PODD) will host an Investor Day on November 20, 2025 at its Acton, Massachusetts headquarters. Presentations begin at 9:00 a.m. ET and are expected to conclude around 12:30 p.m. ET. Management will discuss the company’s longer-term strategic priorities, market opportunities, innovation roadmap, and longer-term financial outlook. Manufacturing tours will be offered after the formal program. The event is in-person by invitation with required registration and will be available via live webcast at the company’s Investor Relations site. A replay and slide deck will be posted on the website after the event.
Insulet Corporation (NASDAQ: PODD) has partnered with Pantone® to create a unique color called Omnipod Mango, a vibrant orange-yellow hue specifically designed for their tubeless insulin pump products. This first-of-its-kind collaboration breaks away from traditional medical device aesthetics, symbolizing the freedom and pride of Omnipod users, known as Podders.
The initiative aims to differentiate the brand and celebrate the diabetes community through color. The Omnipod device is notable as the only waterproof, tubeless, and wearable insulin pump for type 1 and type 2 diabetes patients, providing up to three days of continuous insulin delivery without needles.
Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, has announced a significant leadership change with Flavia Pease appointed as Executive Vice President and Chief Financial Officer, effective September 30, 2025. Pease will succeed Ana Maria Chadwick, who will transition to a Senior Advisor role.
Pease brings extensive healthcare and medical technology experience, most recently serving as CFO at Charles River Laboratories and spending over 20 years at Johnson & Johnson, where she managed a $27 billion global Medical Devices portfolio. As a current Insulet Board member since January 2024, she will resign from the Board upon assuming her new role.
The company also announced it expects to exceed its previously issued Q3 2025 revenue growth guidance, driven by strong new customer acquisition in both U.S. and international markets.
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, has announced significant leadership changes. Eric Benjamin has been promoted to Chief Operating Officer, where he will lead the company's growth and innovation initiatives across new products, markets, and commercial expansion. Additionally, Manoj Raghunandanan joins as Chief Growth Officer, bringing over 20 years of global consumer health leadership experience from Kenvue.
Benjamin, who joined Insulet in 2015, has been crucial in transforming the company through launching products like Omnipod DASH® and Omnipod 5®, expanding into type 2 diabetes markets, and improving customer experience. Raghunandanan will lead Insulet's new Growth organization, focusing on global strategy and commercial capabilities development.
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, has announced its participation in three upcoming investor conferences in September 2025:
• Wells Fargo Healthcare Conference in Boston - September 4 at 3:00 p.m. ET
• Baird Global Healthcare Conference in New York City - September 9 at 12:15 p.m. ET
• Bernstein Insights: Healthcare Leaders & Disruptors Forum in New York City - September 24 at 9:40 a.m. ET
The company will provide live audio webcasts of the presentations, which will be available on their investor relations website. Insulet is known for its Omnipod Insulin Management System, including the innovative Omnipod 5 Automated Insulin Delivery System that integrates with continuous glucose monitoring.
Insulet Corporation (NASDAQ: PODD) reported exceptional Q2 2025 financial results, with total revenue reaching $649.1 million, up 32.9% year-over-year. The company's flagship Omnipod product line generated $639.0 million in revenue, showing strong growth in both U.S. (28.7%) and International (45.0%) markets.
Key financial metrics improved significantly, with gross margin expanding to 69.7% and operating income reaching $121.1 million. The company reported net income of $22.5 million, or $0.32 per diluted share.
Following these strong results, Insulet raised its full-year 2025 guidance, now expecting total revenue growth of 24-27% in constant currency and adjusted operating margin of 17.0-17.5%. Strategic highlights included the expansion of Omnipod 5 compatibility with various CGM sensors across different markets.
Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, will release its second quarter 2025 financial results on August 7, 2025, before markets open. Management will host a conference call at 8:00 a.m. ET the same day.
The company specializes in the Omnipod Insulin Management System, featuring a unique tubeless disposable Pod that provides up to three days of continuous insulin delivery. Their flagship product, the Omnipod 5 Automated Insulin Delivery System, integrates with continuous glucose monitoring and can be controlled via smartphone in the U.S.
FAQ
What is the current stock price of Insulet (PODD)?
What is the market cap of Insulet (PODD)?
